Fig. 3: PD-L2-dependent immune checkpoint blockade therapy.
From: Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy
PD-L2 is highly expressed in antigen-presenting cells and tumour cells, which binds PD-1 to inhibit CD80/86 to CD28 and MHC to TCR signal transduction. After PD-L2-dependent checkpoint blocked therapy, PD-L2 is exhausted, and CD80/86 and MHC activate T cells, thus playing a killing role in the tumour microenvironment (up section). Mechanism of small molecule inhibitors indirectly targeting PD-L2 in different solid tumours (down section).
